Biocon Limited
20th KM Hosur Road
Electronics City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423
CIN : L24234KA1978PLC003417

www.biocon.com

Date of submission: March 6, 2019

To The Secretary BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code - 532523	To The Secretary National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050 Scrip Code- BIOCON

Dear Sir/Madam,

Sub: Biocon Facility Completes Pre Approval U.S. FDA Inspection
Ref: Regulation 30 of SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015

Pursuant to Regulation 30 of the SEBI LODR Regulations, 2015, please find below the "Company Statement" on the subject matter.

*"This is to inform you that the U.S. FDA concluded a pre-approval inspection of Biocon's insulin drug substance manufacturing facility triggered by a New Drug Application submitted by our insulin API customer. The inspection at the Bengaluru facility took place between 25th Feb – 5th Mar, 2019, resulting in a Form 483 with six observations. Biocon is confident of addressing these expeditiously and remains committed to global standards of Quality and Compliance." -**Company Spokesperson***

We request you to kindly take this to your records as per the requirement of LODR and oblige.

Thanking You,
Yours faithfully
For Biocon Limited

Satish Kumar S.S

Satish Kumar S S
Company Secretary & Compliance Officer